The Management of Gonorrhea in the Era of Emerging Antimicrobial Resistance: What Primary Care Clinicians Should Know.

Autor:	Quilter LAS; Division of STD Prevention, Centers of Disease Control and Prevention, 1600 Clifton Road Northeast, MS H24-4, Atlanta, GA 30329, USA. Electronic address: lquilter@cdc.gov., St Cyr SB; Division of STD Prevention, Centers of Disease Control and Prevention, 1600 Clifton Road Northeast, MS H24-4, Atlanta, GA 30329, USA., Barbee LA; Division of STD Prevention, Centers of Disease Control and Prevention, 1600 Clifton Road Northeast, MS H24-4, Atlanta, GA 30329, USA.
Jazyk:	angličtina
Zdroj:	The Medical clinics of North America [Med Clin North Am] 2024 Mar; Vol. 108 (2), pp. 279-296. Date of Electronic Publication: 2023 Sep 14.
DOI:	10.1016/j.mcna.2023.08.015
Abstrakt:	Gonorrhea rates continue to rise in the United States and Neisseria gonorrhoeae's propensity to develop resistance to all therapies used for treatment has complicated the management of gonorrhea. Ceftriaxone is the only remaining highly effective recommended regimen for gonococcal treatment and few new anti-gonococcal antimicrobials are being developed. The 2021 CDC STI Treatment Guidelines increased the dose of ceftriaxone to 500 mg (1 g if ≥ 150 kg) for uncomplicated infections. It is recommended that all clinicians should be aware of antimicrobial resistant gonorrhea and be able to appropriately manage any suspected gonorrhea treatment failure case. Competing Interests: Disclosure S.B. St. Cyr has no conflicts of interest to report. L.A.S. Quilter has no conflicts of interest to report. L.A. Barbee has received research support from Hologic, United States, Nabriva, Ireland and SpeeDx. (Published by Elsevier Inc.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu